Patient-Reported Outcomes With Atezolizumab + Bevacizumab vs Sunitinib in Treatment-Naïve Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Patient-Reported Outcomes From the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab Versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Clin. Cancer Res 2020 Mar 03;[EPub Ahead of Print], MB Atkins, BI Rini, RJ Motzer, T Powles, DF McDermott, C Suarez, S Bracarda, WM Stadler, F Donskov, H Gurney, S Oudard, M Uemura, ET Lam, C Grüllich, C Quach, S Carroll, B Ding, QC Zhu, E Piault-Louis, C Schiff, B EscudierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.